{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:37:49Z","timestamp":1767886669540,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"DOI":"10.7759\/cureus.101071","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:47:06Z","timestamp":1767872826000},"source":"Crossref","is-referenced-by-count":0,"title":["Barriers and Facilitators to Vadadustat Use for Managing Anemia in Adult Patients Undergoing Dialysis: A Qualitative Evidence Synthesis"],"prefix":"10.7759","author":[{"given":"Piercarlo","family":"Minoretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Lista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayvan","family":"Khoramipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Santos-Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enzo","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12061191","article-title":"Anemia of chronic kidney disease - a narrative review of its pathophysiology, diagnosis, and management","volume":"12","author":"Badura K","year":"2024","unstructured":"Badura K, Janc J, W\u0105sik J, et al.. Anemia of chronic kidney disease - a narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024, 12:1191. 10.3390\/biomedicines12061191","journal-title":"Biomedicines"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1718803","article-title":"Eryptosis in renal anemia: mechanisms, clinical implications, and therapeutic targeting","volume":"16","author":"Deng X","year":"2025","unstructured":"Deng X, Gong X, Huang Y, Zhou J, Ren S. Eryptosis in renal anemia: mechanisms, clinical implications, and therapeutic targeting. Front Pharmacol. 2025, 16:1718803. 10.3389\/fphar.2025.1718803","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s J","year":"2021","unstructured":"Portol\u00e9s J, Mart\u00edn L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021, 8:642296. 10.3389\/fmed.2021.642296","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010590.pub3","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","volume":"2","author":"Chung EY","year":"2023","unstructured":"Chung EY, Palmer SC, Saglimbene VM, Craig JC, Tonelli M, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2023, 2:CD010590. 10.1002\/14651858.CD010590.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6087134","article-title":"Erythropoietin dose and mortality in hemodialysis patients: marginal structural model to examine causality","volume":"2016","author":"Streja E","year":"2016","unstructured":"Streja E, Park J, Chan TY, et al.. Erythropoietin dose and mortality in hemodialysis patients: marginal structural model to examine causality. Int J Nephrol. 2016, 2016:6087134. 10.1155\/2016\/6087134","journal-title":"Int J Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1554-0","article-title":"In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study","volume":"20","author":"Ingrasciotta Y","year":"2019","unstructured":"Ingrasciotta Y, Lacava V, Marcian\u00f2 I, et al.. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol. 2019, 20:359. 10.1186\/s12882-019-1554-0","journal-title":"BMC Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000104431","article-title":"Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients","volume":"106","author":"Churchill DN","year":"2007","unstructured":"Churchill DN, Macarios D, Attard C, Kallich J, Goeree R. Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Nephron Clin Pract. 2007, 106:c193-8. 10.1159\/000104431","journal-title":"Nephron Clin Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2174\/0115680266366384250716121432","article-title":"Unveiling vadadustat: comprehensive review of its chemistry, pharmacology, bioanalysis, and patent landscape as a novel HIF-PH inhibitor","author":"Shaikh F","year":"2025","unstructured":"Shaikh F, Sharma S. Unveiling vadadustat: comprehensive review of its chemistry, pharmacology, bioanalysis, and patent landscape as a novel HIF-PH inhibitor. Curr Top Med Chem. 2025, 10.2174\/0115680266366384250716121432","journal-title":"Curr Top Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002951","article-title":"Revolutionizing anemia management in dialysis: unveiling the potential of FDA-approved vadadustat for chronic kidney disease (CKD) patients","volume":"87","author":"Gul MH","year":"2025","unstructured":"Gul MH, Waheed A, Jha M, Wardak AB, Ilma B, Khan U. Revolutionizing anemia management in dialysis: unveiling the potential of FDA-approved vadadustat for chronic kidney disease (CKD) patients. Ann Med Surg (Lond). 2025, 87:1094-6. 10.1097\/MS9.0000000000002951","journal-title":"Ann Med Surg (Lond)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26644","article-title":"Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease","volume":"97","author":"Koury MJ","year":"2022","unstructured":"Koury MJ, Agarwal R, Chertow GM, et al.. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022, 97:1178-88. 10.1002\/ajh.26644","journal-title":"Am J Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt KU","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, et al.. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021, 384:1601-12. 10.1056\/NEJMoa2025956","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000655","article-title":"Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease","volume":"2024","author":"Haase VH","year":"2024","unstructured":"Haase VH, Tanaka T, Koury MJ. Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease. Hematology Am Soc Hematol Educ Program. 2024, 2024:409-18. 10.1182\/hematology.2024000655","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap DY","year":"2021","unstructured":"Yap DY, McMahon LP, Hao CM, et al.. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton). 2021, 26:105-18. 10.1111\/nep.13835","journal-title":"Nephrology (Carlton)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S450464","article-title":"Physician and patient preferences for treatment of anemia associated with chronic kidney disease in Japan: a survey including best-worst scaling","volume":"18","author":"Mishina S","year":"2024","unstructured":"Mishina S, Ito Y, Lee T, Murofushi T, Uetake Y, Akizawa T. Physician and patient preferences for treatment of anemia associated with chronic kidney disease in Japan: a survey including best-worst scaling. Patient Prefer Adherence. 2024, 18:1563-75. 10.2147\/PPA.S450464","journal-title":"Patient Prefer Adherence"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12252","article-title":"Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents","volume":"50","author":"Swaminathan S","year":"2015","unstructured":"Swaminathan S, Mor V, Mehrotra R, Trivedi AN. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. Health Serv Res. 2015, 50:790-808. 10.1111\/1475-6773.12252","journal-title":"Health Serv Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1615809","article-title":"Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis","volume":"16","author":"Yilmaz Y","year":"2025","unstructured":"Yilmaz Y. Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis. Front Pharmacol. 2025, 16:1615809. 10.3389\/fphar.2025.1615809","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-021-01140-0","article-title":"Barriers and facilitators to implementing evidence-based guidelines in long-term care: a qualitative evidence synthesis","volume":"16","author":"McArthur C","year":"2021","unstructured":"McArthur C, Bai Y, Hewston P, Giangregorio L, Straus S, Papaioannou A. Barriers and facilitators to implementing evidence-based guidelines in long-term care: a qualitative evidence synthesis. Implement Sci. 2021, 16:70. 10.1186\/s13012-021-01140-0","journal-title":"Implement Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.795214","article-title":"Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"12","author":"Xiong L","year":"2021","unstructured":"Xiong L, Zhang H, Guo Y, Song Y, Tao Y. Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2021, 12:795214. 10.3389\/fphar.2021.795214","journal-title":"Front Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01383-z","article-title":"Vadadustat: first Approval","volume":"80","author":"Markham A","year":"2020","unstructured":"Markham A. Vadadustat: first Approval. Drugs. 2020, 80:1365-71. 10.1007\/s40265-020-01383-z","journal-title":"Drugs"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2025.100997","article-title":"Vascular access thrombosis events in patients with dialysis-dependent CKD treated with vadadustat or darbepoetin alfa: the INNO2VATE trial program","volume":"7","author":"Winkelmayer WC","year":"2025","unstructured":"Winkelmayer WC, Burke SK, Chertow GM, et al.. Vascular access thrombosis events in patients with dialysis-dependent CKD treated with vadadustat or darbepoetin alfa: the INNO2VATE trial program. Kidney Med. 2025, 7:100997. 10.1016\/j.xkme.2025.100997","journal-title":"Kidney Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow GM","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YM, et al.. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021, 384:1589-600. 10.1056\/NEJMoa2035938","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1198560","article-title":"Pathophysiological concepts and screening of cardiovascular disease in dialysis patients","volume":"3","author":"Echefu G","year":"2023","unstructured":"Echefu G, Stowe I, Burka S, Basu-Ray I, Kumbala D. Pathophysiological concepts and screening of cardiovascular disease in dialysis patients. Front Nephrol. 2023, 3:1198560. 10.3389\/fneph.2023.1198560","journal-title":"Front Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019060575","article-title":"Bundled payment reform and dialysis facility closures in ESKD","volume":"31","author":"Norouzi S","year":"2020","unstructured":"Norouzi S, Zhao B, Awan A, Winkelmayer WC, Ho V, Erickson KF. Bundled payment reform and dialysis facility closures in ESKD. J Am Soc Nephrol. 2020, 31:579-90. 10.1681\/ASN.2019060575","journal-title":"J Am Soc Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000567","article-title":"Safety and efficacy of vadadustat once daily and three times weekly in patients with dialysis-dependent CKD with anemia","volume":"5","author":"Kooienga L","year":"2024","unstructured":"Kooienga L, Burke S, Kathresal A, et al.. Safety and efficacy of vadadustat once daily and three times weekly in patients with dialysis-dependent CKD with anemia. Kidney360. 2024, 5:1652-61. 10.34067\/KID.0000000567","journal-title":"Kidney360"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000380972","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients","volume":"185","author":"Ogawa T","year":"2015","unstructured":"Ogawa T, Nitta K. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol. 2015, 185:76-86. 10.1159\/000380972","journal-title":"Contrib Nephrol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1590\/2175-8239-JBN-2018-0092","article-title":"Functional iron deficiency in patients on hemodialysis: prevalence, nutritional assessment, and biomarkers of oxidative stress and inflammation","volume":"41","author":"Plastina JC","year":"2019","unstructured":"Plastina JC, Obara VY, Barbosa DS, Morimoto HK, Reiche EM, Graciano A, Delfino VD. Functional iron deficiency in patients on hemodialysis: prevalence, nutritional assessment, and biomarkers of oxidative stress and inflammation. J Bras Nefrol. 2019, 41:472-80. 10.1590\/2175-8239-JBN-2018-0092","journal-title":"J Bras Nefrol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/kidneydial2030040","article-title":"Is HIF-PHI the answer to tackle ESA hyporesponsiveness in the elderly?","volume":"2","author":"Wu HH","year":"2022","unstructured":"Wu HH, Chinnadurai R, Walker RJ. Is HIF-PHI the answer to tackle ESA hyporesponsiveness in the elderly?. Kidney Dial. 2022, 2:446-53. 10.3390\/kidneydial2030040","journal-title":"Kidney Dial"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24033037","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism","volume":"24","author":"Ogawa C","year":"2023","unstructured":"Ogawa C, Tsuchiya K, Maeda K. Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism. Int J Mol Sci. 2023, 24:3037. 10.3390\/ijms24033037","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03272-x","article-title":"Real-world safety and effectiveness of vadadustat in patients with chronic kidney disease-related anemia: interim analysis of postmarketing surveillance in Japan","volume":"42","author":"Nangaku M","year":"2025","unstructured":"Nangaku M, Sasaki K, Bi J, Ueta K, Nishimura K, Hashimoto T, Hata M. Real-world safety and effectiveness of vadadustat in patients with chronic kidney disease-related anemia: interim analysis of postmarketing surveillance in Japan. Adv Ther. 2025, 42:4486-509. 10.1007\/s12325-025-03272-x","journal-title":"Adv Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1159\/000455387","article-title":"History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology","volume":"45","author":"Kalantar-Zadeh K","year":"2017","unstructured":"Kalantar-Zadeh K. History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology. Am J Nephrol. 2017, 45:235-47. 10.1159\/000455387","journal-title":"Am J Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-023-00281-2","article-title":"Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case control study","volume":"9","author":"Sakurama K","year":"2023","unstructured":"Sakurama K, Iguchi Y, Haruki S, Hata Y, Hiraga M, Yumoto S, Kai Y. Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case control study. J Pharm Health Care Sci. 2023, 9:13. 10.1186\/s40780-023-00281-2","journal-title":"J Pharm Health Care Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-023-00316-8","article-title":"Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report","volume":"9","author":"Takakura A","year":"2023","unstructured":"Takakura A, Hirai T, Hamaguchi N, Mukohara R, Matsumoto K, Yano Y, Iwamoto T. Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report. J Pharm Health Care Sci. 2023, 9:46. 10.1186\/s40780-023-00316-8","journal-title":"J Pharm Health Care Sci"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_119_23","article-title":"Clinical inertia: a wider perspective and proposed classification criteria","volume":"27","author":"Raveendran AV","year":"2023","unstructured":"Raveendran AV. Clinical inertia: a wider perspective and proposed classification criteria. Indian J Endocrinol Metab. 2023, 27:296-300. 10.4103\/ijem.ijem_119_23","journal-title":"Indian J Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad074","article-title":"Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis","volume":"38","author":"Sarnak MJ","year":"2023","unstructured":"Sarnak MJ, Agarwal R, Boudville N, et al.. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023, 38:2358-67. 10.1093\/ndt\/gfad074","journal-title":"Nephrol Dial Transplant"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2353341","article-title":"Medication burden in patients with dialysis-dependent CKD: a systematic review","volume":"46","author":"Liu X","year":"2024","unstructured":"Liu X, Chen P, Liu Y, Jia X, Xu D. Medication burden in patients with dialysis-dependent CKD: a systematic review. Ren Fail. 2024, 46:2353341. 10.1080\/0886022X.2024.2353341","journal-title":"Ren Fail"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.13214","article-title":"The impact of medication regimen complexity on patient-related and clinical outcomes in patients undergoing hemodialysis","volume":"29","author":"Goh JX","year":"2025","unstructured":"Goh JX, Tesfaye W, Van C, Sud K, Seth S, Tarafdar S, Castelino RL. The impact of medication regimen complexity on patient-related and clinical outcomes in patients undergoing hemodialysis. Hemodial Int. 2025, 29:231-6. 10.1111\/hdi.13214","journal-title":"Hemodial Int"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783x-14-5-185","article-title":"Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature","volume":"14","author":"Schmid H","year":"2009","unstructured":"Schmid H, Hartmann B, Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res. 2009, 14:185-90. 10.1186\/2047-783x-14-5-185","journal-title":"Eur J Med Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.04.030","article-title":"Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23","volume":"100","author":"Ikeda Y","year":"2021","unstructured":"Ikeda Y. Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23. Kidney Int. 2021, 100:14-6. 10.1016\/j.kint.2021.04.030","journal-title":"Kidney Int"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy055","article-title":"Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents","volume":"34","author":"Haase VH","year":"2019","unstructured":"Haase VH, Chertow GM, Block GA, et al.. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2019, 34:90-9. 10.1093\/ndt\/gfy055","journal-title":"Nephrol Dial Transplant"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1159\/000521162","article-title":"Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease","volume":"8","author":"Wu HH","year":"2022","unstructured":"Wu HH, Chinnadurai R. Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease. Kidney Dis (Basel). 2022, 8:103-14. 10.1159\/000521162","journal-title":"Kidney Dis (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-023-02432-z","article-title":"Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies","volume":"28","author":"Nangaku M","year":"2024","unstructured":"Nangaku M, Ueta K, Nishimura K, Sasaki K, Hashimoto T. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies. Clin Exp Nephrol. 2024, 28:391-403. 10.1007\/s10157-023-02432-z","journal-title":"Clin Exp Nephrol"},{"key":"ref42","unstructured":"Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease. (2025). Accessed. December 9, 2025: https:\/\/www.nice.org.uk\/guidance\/ta1035."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.09.006","article-title":"Vadadustat three times weekly in patients with anemia due to dialysis-dependent CKD","volume":"85","author":"Toka HR","year":"2025","unstructured":"Toka HR, Bernardo M, Burke SK, et al.. Vadadustat three times weekly in patients with anemia due to dialysis-dependent CKD. Am J Kidney Dis. 2025, 85:454-464.e1. 10.1053\/j.ajkd.2024.09.006","journal-title":"Am J Kidney Dis"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.12932\/AP-040719-0592","article-title":"Epoetin-alfa induced pruritic maculopapular eruption: case report and literature review","volume":"41","author":"Rueangsri R","year":"2023","unstructured":"Rueangsri R, Laisuan W. Epoetin-alfa induced pruritic maculopapular eruption: case report and literature review. Asian Pac J Allergy Immunol. 2023, 41:231-5. 10.12932\/AP-040719-0592","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2016.11.003","article-title":"The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism","volume":"4","author":"Lv X","year":"2017","unstructured":"Lv X, Li J, Zhang C, et al.. The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis. 2017, 4:19-24. 10.1016\/j.gendis.2016.11.003","journal-title":"Genes Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku M","year":"2021","unstructured":"Nangaku M, Kondo K, Ueta K, et al.. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant. 2021, 36:1731-41. 10.1093\/ndt\/gfab055","journal-title":"Nephrol Dial Transplant"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad298","article-title":"Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations","volume":"17","author":"Sackeyfio A","year":"2024","unstructured":"Sackeyfio A, Lopes RD, Kovesdy CP, et al.. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations. Clin Kidney J. 2024, 17:sfad298. 10.1093\/ckj\/sfad298","journal-title":"Clin Kidney J"},{"key":"ref48","article-title":"A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease","volume":"15","author":"Chen J","year":"2023","unstructured":"Chen J, Shou X, Xu Y, et al.. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease. Aging (Albany NY). 2023, 15:2237-74.","journal-title":"Aging (Albany NY)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/23743735241302941","article-title":"Patient engagement in evidence-based practice frameworks","volume":"11","author":"Dusin J","year":"2024","unstructured":"Dusin J, Peltzer J. Patient engagement in evidence-based practice frameworks. J Patient Exp. 2024, 11:10.1177\/23743735241302941","journal-title":"J Patient Exp"},{"key":"ref50","article-title":"Value of the pharmacist in the medication reconciliation process","volume":"41","author":"Splawski J","year":"2016","unstructured":"Splawski J, Minger H. Value of the pharmacist in the medication reconciliation process. P T. 2016, 41:176-8.","journal-title":"P T"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2491655","article-title":"HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database","volume":"47","author":"Wu D","year":"2025","unstructured":"Wu D, Jiao S, Lin H, Xie P, Cai G, Lin M. HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database. Ren Fail. 2025, 47:2491655. 10.1080\/0886022X.2025.2491655","journal-title":"Ren Fail"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari S","year":"2025","unstructured":"Bhandari S, Spencer S, Oliveira B, et al.. UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease. BMC Nephrol. 2025, 26:193. 10.1186\/s12882-025-04115-1","journal-title":"BMC Nephrol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy174","article-title":"Cardiovascular disease in dialysis patients","volume":"33","author":"Cozzolino M","year":"2018","unstructured":"Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018, 33:iii28-34. 10.1093\/ndt\/gfy174","journal-title":"Nephrol Dial Transplant"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04020-2","article-title":"A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024","volume":"398","author":"Aksoyalp ZS","year":"2025","unstructured":"Aksoyalp ZS, Kayki-Mutlu G, Wojnowski L, Michel MC. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. Naunyn Schmiedebergs Arch Pharmacol. 2025, 398:5077-99. 10.1007\/s00210-025-04020-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01498","article-title":"Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: a historical perspective","volume":"9","author":"Aapro M","year":"2018","unstructured":"Aapro M, Gasc\u00f3n P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J. Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: a historical perspective. Front Pharmacol. 2018, 9:1498. 10.3389\/fphar.2018.01498","journal-title":"Front Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01537-6","article-title":"Navigating diverging perspectives: reasoning, evidence, and decision-making in drug safety","volume":"48","author":"Hammad TA","year":"2025","unstructured":"Hammad TA, Davies S. Navigating diverging perspectives: reasoning, evidence, and decision-making in drug safety. Drug Saf. 2025, 48:587-93. 10.1007\/s40264-025-01537-6","journal-title":"Drug Saf"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2023.12.003","article-title":"Shared decision-making and patient communication in nephrology practice","volume":"31","author":"Mandel EI","year":"2024","unstructured":"Mandel EI, Fox M, Schell JO, Cohen RA. Shared decision-making and patient communication in nephrology practice. Adv Kidney Dis Health. 2024, 31:5-12. 10.1053\/j.akdh.2023.12.003","journal-title":"Adv Kidney Dis Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449323-barriers-and-facilitators-to-vadadustat-use-for-managing-anemia-in-adult-patients-undergoing-dialysis-a-qualitative-evidence-synthesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:47:07Z","timestamp":1767872827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449323-barriers-and-facilitators-to-vadadustat-use-for-managing-anemia-in-adult-patients-undergoing-dialysis-a-qualitative-evidence-synthesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.101071","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}